Physician profile
Mark Kovacik
NPI 1275552606
$306.01
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84.43 | 2019 | |
| Ucb, INC. | $63.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.96 | 2019 | |
| Adamas Pharmaceuticals, INC. | $22.46 | 2019 | |
| Akcea Therapeutics, INC. | $20.88 | 2019 | |
| Acorda Therapeutics, INC | $14.48 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.35 | 2019 | |
| Biogen, INC. | $13.31 | 2019 | |
| Glaxosmithkline, LLC. | $11.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kovacik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.